A&G Pharmaceutical, Inc. is organized around development to in-use conditon of theranostic products and drug/test combinations that enhance screening, detection, and treatment of cancer and other human diseases. The company primarily focuses on developing molecular tests that detect cancer at earlier stages when it is treatable and develops associated treatments that precisely target and destroy cancer. It offers GP88/progranulin, a biomarker produced by breast cancer tumors and used to help the cancer grow and proliferate. The company provides GP88-based breast cancer diagnostic test kits to enhance early detection, diagnosis, and treatment of breast cancer. It also focuses on developing anti-GP88 monoclonal antibody therapeutics; and screening for monoclonal antibodies that recognize ovarian, pancreatic, prostate, and lung cancer. The aim is to develop personalized approaches to treating cancer.
